MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- BSE Healthcare
- Losers Today
Losers Today 
:
BSE Healthcare
Here are the top losers today from the BSE Healthcare index. To know more about the Index, please visit the BSE Healthcare Live Chart. Also read our detailed report on the pharmaceuticals sector.
Date: Apr 18, 2019 (Close)
| COMPANY | PRICE (Rs) | CHANGE (%) | VOLUME ('000) | DAY'S H/L (Rs) | 52-WEEK H/L (Rs) | GET MORE INFO |
|---|---|---|---|---|---|---|
| S&P BSE SENSEX | 39,140.28 | -0.3% | - | 39,487 / 39,083 | 39,487 / 33,292 | More Info
|
| NIFTY 50 | 11,752.80 | -0.3% | - | 11,856 / 11,739 | 11,856 / 10,005 | More Info
|
| S&P BSE HEALTHCARE | 14,480.77 | -0.3% | - | 14,566 / 14,403 | 16,497 / 12,606 | More Info
|
| RPG LIFE SCIENCES | 242.40 | -3.4% | 1.8 | 254 / 241 | 440 / 202 | More Info
|
| MEDICAMEN BI | 520.45 | -3.3% | 4.4 | 556 / 506 | 709 / 390 | More Info
|
| WOCKHARDT | 439.10 | -3.2% | 120.5 | 456 / 437 | 853 / 375 | More Info
|
| NATCO PHARMA | 541.75 | -3.2% | 25.6 | 564 / 540 | 849 / 540 | More Info
|
| MERCK | 3,781.85 | -2.9% | 5.2 | 3,925 / 3,755 | 3,990 / 1,540 | More Info
|
| ABBOTT INDIA | 7,810.95 | -2.8% | 0.2 | 8,054 / 7,777 | 8,834 / 6,027 | More Info
|
| GUFIC BIOSCIENCE | 87.55 | -2.8% | 7.8 | 90 / 87 | 164 / 65 | More Info
|
| MARKSANS PHARMA. | 25.00 | -2.7% | 122.0 | 26 / 25 | 41 / 22 | More Info
|
| HIKAL LTD. | 177.85 | -2.7% | 36.3 | 185 / 175 | 207 / 135 | More Info
|
| LINCOLN PHAR | 192.90 | -2.6% | 3.1 | 200 / 190 | 314 / 157 | More Info
|
| PANACEA BIOTECH | 201.70 | -2.5% | 8.2 | 208 / 200 | 301 / 138 | More Info
|
| HEALTHCARE GLOBAL ENTER. | 202.00 | -2.4% | 0.3 | 209 / 202 | 335 / 179 | More Info
|
| ALEMBIC LTD | 43.60 | -2.4% | 15.3 | 45 / 43 | 61 / 36 | More Info
|
| BLISS GVS PHARMA | 174.60 | -2.3% | 64.0 | 180 / 174 | 225 / 125 | More Info
|
| INDOCO REMEDIES | 198.80 | -2.3% | 2.7 | 202 / 197 | 238 / 150 | More Info
|
| SUN PHARMA ADV. RES. | 179.60 | -2.2% | 39.7 | 185 / 178 | 438 / 141 | More Info
|
| CAPLIN POINT | 384.95 | -2.1% | 1.6 | 392 / 383 | 619 / 305 | More Info
|
| SHALBY LTD | 135.10 | -1.8% | 1.4 | 138 / 134 | 233 / 123 | More Info
|
| J.B.CHEMICALS | 347.75 | -1.7% | 6.7 | 354 / 343 | 373 / 236 | More Info
|
| IOL CHEMICALS & PHARM. | 190.50 | -1.7% | 29.3 | 196 / 188 | 225 / 78 | More Info
|
| THYROCARE TECHNOLOGIES | 511.20 | -1.5% | 1.3 | 520 / 509 | 725 / 482 | More Info
|
| ERIS LIFESCIENCES LIMITED | 627.90 | -1.5% | 0.2 | 637 / 623 | 809 / 572 | More Info
|
| STRIDES PHARMA SCIENCE | 488.25 | -1.5% | 32.5 | 497 / 484 | 658 / 334 | More Info
|
| LAURUS LABS LTD | 395.50 | -1.3% | 5.1 | 400 / 389 | 517 / 324 | More Info
|
| BIOCON | 615.30 | -1.3% | 27.5 | 624 / 613 | 718 / 544 | More Info
|
Circuit Breaker (up)
Circuit Breaker (down) * Mutual Funds that hold this stock
|
| |
Today's Market
Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)
Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.
Related Views on News
MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)
Mar 5, 2019 | Updated on Mar 5, 2019For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)
Apr 9, 2019It's a matter of time before the stocks catch the fancy of the markets and big investors.
3 Indian Stocks with Amazon-Like Potential(Profit Hunter)
Apr 10, 2019We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.
A 90% Chance of Auto Stocks Moving Up This April(Profit Hunter)
Apr 5, 2019The Auto index ended on a positive note in the month of April in 9 out of last 10 years. This Auto stock is best placed to benefit from the upswing in this sector.
This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)
Apr 10, 2019How Dell got its mojo back.
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
More|
| |
S&P BSE HEALTHCARE
Apr 18, 2019 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.